Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor which is being combined here to further augment the immune activity of the vaccine. Citarinostat has not been approved by the FDA as a treatment for any disease.
|Developed By||Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb|
|Additional Names||ACY-241, CC-96241|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
There are no resources, links or videos to display for this treatment.